Search Within

Claire Frances Friedman

Formats
  1. Meeting Abstract (59)
  2. Journal Article (53)
  3. Editorial (2)
  4. Book Section (1)
  5. Guidelines (1)
  6. Research Letter (1)
  7. Review (1)
Groups
  1. Department of Medicine (118)
  2. GDMT, Medicine (118)
  3. Gynecologic Medicine Service (118)
  4. Gynecology Disease Management Team (118)
  5. Solid Tumor Oncology Division (118)
  6. Weinberg Fellows (118)

More Groups

People
  1. Carol Aghajanian (43)
  2. Dmitriy Zamarin (40)
  3. Britta Weigelt (31)
  4. Roisin O'Cearbhaill (30)
  5. Nadeem Abu-Rustum (26)
  6. Vicky Makker (26)

More People

Years
  1. 2025 (6)
  2. 2024 (19)
  3. 2023 (11)
  4. 2022 (29)
  5. 2021 (12)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (25)
  2. Gynecologic Oncology (18)
  3. Annals of Oncology (11)
  4. International Journal of Gynecological Cancer (10)
  5. Journal for ImmunoTherapy of Cancer (10)
  6. Clinical Cancer Research (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (26)
  2. Elsevier Inc. (21)
  3. American Association for Cancer Research (14)
  4. Oxford University Press (14)
  5. Biomed Central Ltd (10)
  6. Lippincott Williams & Wilkins (10)

More Publishers

Results (118)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: A case series
    Journal Article

    Sia, T. Y.; Manning-Geist, B.; Gordhandas, S.; Murali, R.; Marra, A.; Liu, Y. L.; Friedman, C. F.; Hollmann, T. J.; Zivanovic, O.; Chi, D. S.; more...
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save
  • Small cell neuroendocrine carcinoma of the cervix: Analysis of prognostic factors and patterns of metastasis
    Journal Article

    Gordhandas, S.; Schlappe, B. A.; Zhou, Q.; Iasonos, A.; Leitao, M. M. Jr; Park, K. J.; de Brot, L.; Alektiar, K. M.; Sabbatini, P. J.; Aghajanian, C. A.; more...
    Gynecologic Oncology Reports (2022)

    Fulltext@MSK | Save
  • DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A subgroup analysis of a phase 1/2 multicenter study
    Meeting Abstract

    Patel, M. R.; Johnson, M. L.; Falchook, G. S.; Doi, T.; Friedman, C. F.; Piha-Paul, S. A.; Gutierrez, M.; Shimizu, T.; Cheng, B.; Qian, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study
    Journal Article

    Friedman, C. F.; Hainsworth, J. D.; Kurzrock, R.; Spigel, D. R.; Burris, H. A. 3rd; Sweeney, C. J.; Meric-Bernstam, F.; Wang, Y.; Levy, J.; Grindheim, J.; more...
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses
    Journal Article

    Friedman, C. F.; Spencer, C.; Cabanski, C. R.; Panageas, K. S.; Wells, D. K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade
    Meeting Abstract

    Muroyama, Y.; Manne, S.; Greenplate, A.; Mathew, D.; Oldridge, D.; Chilukuri, L.; Xu, C.; Herati, R.; Huang, A.; Zamarin, D.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors
    Meeting Abstract

    Meric-Bernstam, F.; Hainsworth, J.; Bose, R.; Burris, H. A. 3rd; Friedman, C. F.; Kurzrock, R.; Swanton, C.; Wang, Y.; Levy, J.; Schulze, K.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Provision of subspecialized expert oncology (SEO) opinions using Navya Cancer Data Model (NCDM), a technology-based platform: Prospective study to facilitate access to care
    Meeting Abstract

    Traina, T. A.; Kantoff, P. W.; Matasar, M. J.; Dunn, L.; Friedman, C. F.; Voss, M. H.; Seidman, A. D.; Cahlon, O.; Zauderer, M. G.; Manship, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
    Journal Article

    Navitski, A.; Al-Rawi, D. H.; Liu, Y.; Rubinstein, M. M.; Friedman, C. F.; Rampal, R. K.; Mandelker, D. L.; Cadoo, K.; O'Cearbhaill, R. E.
    Gynecologic Oncology Reports (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save